Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This is a dose-ranging study to evaluate the efficacy, safety and tolerability of a range of
doses of a biphasic formulation of remogliflozin etabonate compared to placebo, administered
over 12 weeks in subjects with type 2 diabetes mellitus.